{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-109353","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2026-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.384656+00:00","generated_at":"2026-05-15T10:47:24.151267+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Monte Rosa posts Q4 net loss $46.1M; cash runway into 2029; positive Phase 1 data for NEK7 degrader MRT-8102","bullets":["Q4 net loss $46.1M vs $13.4M in Q4 2024; full-year net loss decreased to $38.6M from $72.7M.","Cash, equivalents, securities $382.1M at Dec 31, 2025; $345M Jan 2026 offering extends runway into 2029.","Interim Phase 1 data for NEK7 degrader MRT-8102: 85% CRP reduction in elevated CVD-risk subjects; unblinded safety shows no SAEs.","Plans to initiate multiple Phase 2 studies of MRT-8102 in H2 2026 (ASCVD, gout, hidradenitis suppurativa).","MRT-2359 in mCRPC with AR mutations: 100% PSA response rate; Phase 2 with apalutamide planned Q3 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-109353","json":"https://secwatch.observer/filing/0001193125-26-109353.json","markdown":"https://secwatch.observer/filing/0001193125-26-109353.md","text":"https://secwatch.observer/filing/0001193125-26-109353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526109353/0001193125-26-109353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526109353/glue-20260317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T10:47:24.151267+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}